Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;128(6):1165-74.
doi: 10.1016/j.jaci.2011.10.024.

Asthma exacerbations: origin, effect, and prevention

Affiliations
Review

Asthma exacerbations: origin, effect, and prevention

David J Jackson et al. J Allergy Clin Immunol. 2011 Dec.

Abstract

Asthma is the most common chronic respiratory disease, affecting up to 10% of adults and 30% of children in the Western world. Despite advances in asthma management, acute exacerbations continue to occur and impose considerable morbidity on patients and constitute a major burden on health care resources. Respiratory tract viruses have emerged as the most frequent triggers for exacerbations in both children and adults; however, the mechanisms underlying these remain poorly understood. More recently, it has become increasingly clear that interactions might exist between viruses and other triggers, increasing the likelihood of an exacerbation. In this article we begin with an overview of the health, economic, and social burden that exacerbations of asthma carry with them. This is followed by a review of the pathogenesis of asthma exacerbations, highlighting the various triggers responsible and multiple interactions that exist between them. The final section first addresses what preventative measures are currently available for asthma exacerbations and subsequently examines which of the new treatments in development might lessen the burden of exacerbations in the future.

PubMed Disclaimer

Figures

Fig 1
Fig 1
The annual cycle of asthma hospitalization in children aged 2 to 15 years in Canada from 1990 to 2004 expressed as multiples of the within-year weekly mean number of hospitalizations showing epidemic peak occurring in September every year.
Fig 2
Fig 2
Kaplan-Meier estimates of cumulative risk of hospital admission with wheeze or asthma during the first 8 years of life stratified on 5-class model. A, Age at first hospital admission for children who had a hospital admission with wheeze or asthma at any age. B, Age at first hospital admission among children who had a hospital admission after age 3 years. A significant increase in the risk of hospital admission with acute asthma is seen only among children in the multiple early class, but not among those in any of the other atopy classes.

References

    1. O’Byrne P.M., Barnes P.J., Rodriguez-Roisin R. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–1397. - PubMed
    1. Pauwels R.A., Lofdahl C.G., Postma D.S. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group [published erratum appears in N Engl J Med 1998;338:139] N Engl J Med. 1997;337:1405–1411. - PubMed
    1. Hanania N.A., Alpan O., Hamilos D.L. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med. 2011;154:573–582. - PubMed
    1. Griswold S.K., Nordstrom C.R., Clark S., Gaeta T.J., Price M.L., Camargo C.A., Jr. Asthma exacerbations in North American adults: who are the “frequent fliers” in the emergency department? Chest. 2005;127:1579–1586. - PubMed
    1. Miller M.K., Lee J.H., Miller D.P., Wenzel S.E. Recent asthma exacerbations: a key predictor of future exacerbations. Respir Med. 2007;101:481–489. - PubMed

Publication types

MeSH terms